Tel Aviv-based Aidoc, which develops AI tools for radiologists to analyze CT scans and X-rays, raised a $110M Series D, bringing its total funding to ~$250M
Andrea Park / Fierce Biotech :
Context & Ripple Effects
Aidoc's $110M Series D is the fourth step in a steady escalation: after a $27M Series B in 2019, a $20M extension, and a $66M round led by General Catalyst in 2021, this raise roughly quadruples its total capital to about $250M in three years.
The cadence matters more than any single check — subsequent coverage shows Aidoc going on to raise another $150M led by General Catalyst and Square Peg with NVIDIA's NVentures and U.S. health systems participating, then a $150M Series E taking total funding to $520M, suggesting this Series D was the inflection where clinical imaging AI moved into big-capital territory.
First-order effects
- Aidoc gains the balance sheet to scale its CT and X-ray triage tools across hospital systems while rivals in radiology AI are still raising at Series B/C scale.
- General Catalyst, which led the prior round, deepens its position in a company now positioned as the category's best-funded player.
Second-order effects
- Competing scan-analysis vendors face pressure to match the war chest or differentiate on clinical scope, since hospital buyers increasingly weigh vendor longevity in multi-year imaging-AI contracts.
- Strategic and healthcare-system capital — visible later via NVIDIA's NVentures and four major U.S. health systems joining Aidoc's cap table — becomes the follow-on playbook, pulling payers and providers directly into financing clinical AI.
Third-order effects
- If the pattern holds, radiology AI consolidates around a few heavily capitalized platforms that bundle multiple findings and specialties per scan, squeezing out single-algorithm point solutions.
- Tel Aviv's emergence alongside hubs like Bengaluru and Shenzhen gets another data point: Israel-origin medical AI companies can reach half-billion-dollar cumulative funding without relocating.
The trend: Clinical imaging AI is following a venture arc of ever-larger rounds as vendors expand from single finding-detection tools toward platform-scale decision support, with strategic investors and health systems replacing pure financial backers at the top of the stack.